Search

everythinglearnresearchcommunity

for

Search:↓

New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.

Maximum serum DHT suppression for finasteride occurs at 8 hours, while for dutasteride, it occurs within 1 to 2 weeks with daily dosing. Dutasteride mesotherapy will be followed by blood tests to check serum DHT changes.

An 18-year-old male stopped using finasteride due to side effects and plans to start topical dutasteride, considering it a potential solution with fewer side effects. He continues using minoxidil despite no noticeable results and is exploring other treatments like RU58841.

The user is considering using dutasteride or finasteride for hair loss and has recurrent folliculitis. Another user suggests treating the folliculitis and notes diffuse thinning.

User Topher1999 achieved hair regrowth using Dutasteride 3 times a week and microneedling with Dr. Pen Ultima A6 every 2 weeks for 9 months. They believe microneedling is the main reason for hairline gains.

RU58841 remains active for several hours after application, and it's suggested to wait a few hours before washing it off to maintain its effectiveness. There is a concern about potential transfer to others if they touch the hair shortly after application.

A user shared 3 months of hair loss progress using topical minoxidil 5%, biotin, and increased protein. The user noted steady improvement and the benefit of progress pictures.

User reports being on finasteride for 3 months, experiencing initial shedding but noticing new hair growth and increased density. They also started using castor oil daily and considered trimming their long hair to improve visual thickness.

Finding a topical solution for hair loss, with specific treatments mentioned such as Minoxidil, Finasteride and RU58841.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.